ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

SENS Senseonics Holdings Inc

0.4714
-0.0156 (-3.20%)
02 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Senseonics Holdings Inc AMEX:SENS AMEX Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  -0.0156 -3.20% 0.4714 0.487 0.456 0.4799 1,276,736 00:59:18

Senseonics Holdings, Inc. Schedules Third Quarter 2022 Earnings Release and Conference Call for November 8, 2022, at 4:30 p.m. Eastern Time

25/10/2022 9:05pm

Business Wire


Senseonics (AMEX:SENS)
Historical Stock Chart


From May 2022 to May 2024

Click Here for more Senseonics Charts.

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its third quarter 2022 financial results after market close on Tuesday, November 8, 2022.

Management will hold a conference call to review the Company’s third quarter 2022 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference. To listen to the conference call, please dial 1-888-317-6003 (US/Canada) or 1-412-317-6061 (International), passcode 1126379, approximately ten to five minutes prior to start time.

About Senseonics

Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems, Eversense®, Eversense® XL and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

Senseonics Investor Contact Philip Taylor Investor Relations 415-937-5406 investors@senseonics.com

1 Year Senseonics Chart

1 Year Senseonics Chart

1 Month Senseonics Chart

1 Month Senseonics Chart

Your Recent History

Delayed Upgrade Clock